Menu
← Company library
United States / Company briefSources checked 2026-10-03

Amgen Inc.

Amgen

Develops and markets biologic medicines across disease areas and advances obesity and metabolic candidates.

01

Products & pipeline

MariTide / maridebart cafraglutide

Phase 3

Reported ongoing MARITIME-1 and MARITIME-2 phase 3 studies for weight management.

As of 2026-08-04Amgen ↗
02

Recent developments

Progress reported

Reported enrollment in MariTide phase 3 studies covering cardiovascular outcomes, heart failure and sleep apnea.

Amgen ↗
03

Experience in official career sources

Individual vacancy

Inflammation Research - In Vivo Pharmacology Scientist

Applications observed open

Observed 2026-10-03

Work
Conducts in vivo inflammation and autoimmune disease model studies, ex vivo assays and cross-functional work.
Experience & requirements
Basic Qualifications lists a doctorate, or a related master’s plus 2 years in biotech/pharma, or a bachelor’s plus 4 years. The body requires rodent, cellular/biochemical assay and multicolor flow-cytometry experience.
Official source ↗
Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. Amgen Reports Second Quarter 2026 Financial Results ↗Amgen · Published 2026-08-04 · Sources checked 2026-10-03
  2. Inflammation Research - In Vivo Pharmacology Scientist ↗Amgen · Published 2026-09-17 · Sources checked 2026-10-03